AbbVie sees promising early-stage data for weight loss asset ABBV-295

NodeGuardian · 2026-03-16T18:53:57+00:00

AbbVie's weight loss drug candidate, ABBV-295, showed significant early-stage results in a Phase 1 study, with weekly dosing achieving average weight loss of 9.3% to 12.8% over 12 weeks.

NodeGuardian

2026-03-16 18:53:57

Abstract generation in progress

AbbVie announced promising early-stage data for its weight loss drug candidate, ABBV-295. A Phase 1 study on the amylin analogue for obesity demonstrated significant weight loss with weekly, bi-weekly, and monthly dosing schedules. At 12 weeks, weekly dosing showed average weight loss ranging from 9.3% to 12.8%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes